Natural Medicine – 1 June 2013
elev8TM tablets represent a new generation of validated natural herbal medicine that has been researched in collaboration with an international team of scientists and clinicians, according to global practice. Zembrin®, the active extract in elevarm tablets, is one of the most thoroughly studied standardised medicinal plant extracts on the international market.
elev8TM tablets assist in reducing stress levels, elevating mood and reducing feelings of anxiety for all people at all stages of life. Users have reported a feeling of ‘calm focus’, ‘alert serenity’ and ‘relaxation without drowsiness’.
elev8TM tablets act rapidly. Positive effects are typically experienced between days one to two of consumption. Once a day dosing allows for seamless incorporation into your daily routine.
Zembrin®, extract of Sceletium tortuosum, has been thoroughly studied for safety and efficacy 12,31 in three clinical trials and carries the GRAS (Generally Regarded As Safe) status in the USA. The three clinical studies have been submitted for publication and the first is already published.
elev8TM tablets could be prescribed or recommended by a medical practitioner for stress, anxiety and low mood not severe enough to be classified in terms of DSM IV criteria [41 to warrant a pharmaceutical antidepressant or anxiolytic.
elev8 tablets are available in packs of 10’s and 30’s and are available without prescription from most pharmacies, nationwide.
Zembrin® has received recognition in numerous fields including:
Scientific and medical The Zembrin® Research and Development team were the first to identify, patent and publish the action of Zembrine. (Patents: US#6,288,104, new patent applications: PCT/IB2010/051132; Harvey et al. 2011). Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. Journal of Ethnopharmacology.
Environmental elev8TM tablets are environmentally friendly; no wild stocks of plant are used. Zembrin® is extracted from a unique naturally occurring variety of Sceletium that has been successfully developed as a new commercial crop for the first time.
The developers of Zembrine, HG&H Pharmaceuticals (Pty) Ltd., have been ceremonially awarded the first Bioprospecting and Export Permit ever issued in South Africa (Permit number IEP0001)(Integrated Export and Bioprospecting Permit).
The developers of Zembrine have concluded the first African ‘prior informed consent’ benefit sharing agreement with the South African San Council as beneficiaries, demonstrated by the logo of the South African San Council on the package.
Haylene N. et al. A Randomized, Double-Blind, Parallel-Group, PlaceboControlled Trial of Extract Sceletium tortuosum (Zembrin®) in Healthy Adults. Journal of Alternative and Complementary Medicine Online Ahead of Print: February 26, 2013. Terburg D. et al. Acute effects of Sceletium tortuosum (Zembrine”), a dual 5-11T reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Status: Paper submitted for peer review. Chiu S. et al. Randomized controlled study of extract Sceletium tortuosum (Zembring”), prototypal Phosphodiesterase subtype-4 ( PDE-4 ) modulator on cognition in healthy adults : implications for targeting PDE-4 in Alzheimer’s Dementia. Status : Paper submitted for peer review The Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association provides a common language and standard criteria for the classification of mental disorders: Wikipedia n.d., Diagnostic and Statistical Manual of Mental Disorders, viewed 3 May 2013: http://en.wikipedia.org/wiki/Diagnostic_and_statistical_manual_of_ mental_disorders